Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen

ConclusionThe recruited population in the ongoing NEURO-TTRansform study has global representation characteristic of contemporary clinical practice.Trial RegistrationClinicalTrials.gov identifier NCT04136184.
Source: Neurology and Therapy - Category: Neurology Source Type: research